Development of a dietary formulation of the SHetA2 chemoprevention drug for mice
Open Access
- 22 December 2017
- journal article
- research article
- Published by Springer Nature in Investigational New Drugs
- Vol. 36 (4) , 561-570
Abstract
Summary: Development of cancer chemoprevention compounds requires enhanced consideration for toxicity and route of administration because the target population is healthy. The small molecule drug, SHetA2 (NSC 726189), exhibited in vivo chemoprevention activity and lack of toxicity when administered by oral gavage. Our objective was to determine if a dietary formulation of SHetA2 could achieve effective tissue drug levels without toxicity. C57bl/6 J mice were monitored on modified American Institute of Nutrition (AIN)76A diet mixed with SHetA2 in a 3:1 ratio with Kolliphor HS15, a self-emulsifying drug delivery system (SEDDS) to deliver 37.5, 62.5, 125, 187 or 250 mg SHetA2/kg/day. Blood and tissues were evaluated after 1, 3 and 6 weeks. The 187 mg/kg/day dose was identified as optimal based on achievement of maximum blood and tissue drug levels in the effective micromolar range without evidence of toxicity. The 250 mg/kg/day group exhibited lower drug levels and the highest intestinal drug content suggesting that an upper limit of intestinal absorption had been surpassed. Only this highest dose resulted in liver and kidney function tests that were outside of the normal range, and significant reduction of cyclin D1 protein in normal cervical tissue. SHetA2 reduced cyclin D1 to greater extents in cancer compared to non-cancer cell cultures. Given this differential effect, optimal chemoprevention without toxicity would be expected to occur at doses that reduced cyclin D1 in neoplastic, but not in normal tissues. These findings support further development of SHetA2 as a chemoprevention agent and potential food additive.Keywords
Funding Information
- National Cancer Institute (7-8481381, R01CA196200, R01 CA200126)
- National Institutes of Health (8P20GM103447)
This publication has 20 references indexed in Scilit:
- Chemoprevention of Colon and Small Intestinal Tumorigenesis in APCmin/+ Mice By SHetA2 (NSC721689) without ToxicityCancer Prevention Research, 2013
- Oral toxicity and pharmacokinetic studies of SHetA2, a new chemopreventive agent, in rats and dogsDrug and Chemical Toxicology, 2012
- NF-κB is involved in SHetA2 circumvention of TNF-α resistance, but not induction of intrinsic apoptosisAnti-Cancer Drugs, 2010
- Cyclin D1 Degradation Is Sufficient to Induce G1 Cell Cycle Arrest despite Constitutive Expression of Cyclin E2 in Ovarian Cancer CellsCancer Research, 2009
- Metabolism of a sulfur‐containing heteroarotionoid antitumor agent, SHetA2, using liquid chromatography/tandem mass spectrometryRapid Communications in Mass Spectrometry, 2008
- Flexible heteroarotinoid (Flex-Het) SHetA2 inhibits angiogenesis in vitro and in vivoInvestigational New Drugs, 2008
- Flex-Hets differentially induce apoptosis in cancer over normal cells by directly targeting mitochondriaMolecular Cancer Therapeutics, 2007
- High performance liquid chromatographic analysis and preclinical pharmacokinetics of the heteroarotinoid antitumor agent, SHetA2Cancer Chemotherapy and Pharmacology, 2006
- Flexible heteroarotinoids (Flex-Hets) exhibit improved therapeutic ratios as anti-cancer agents over retinoic acid receptor agonistsInvestigational New Drugs, 2005
- Synthesis of Flexible Sulfur-Containing Heteroarotinoids That Induce Apoptosis and Reactive Oxygen Species with Discrimination between Malignant and Benign CellsJournal of Medicinal Chemistry, 2004